BALB/c mice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production

PLoS Neglected Tropical Diseases

Volumn 5, Issue 3, 2011, Pages

  Costa, Diego L ^a   Carregaro, Vanessa ^a   Lima Júnior, Djalma S ^a   Silva, Neide M ^b   Milanezi, Cristiane M ^a   Cardoso, Cristina R ^c   Giudice, Ângela ^d   de Jesus, Amélia R ^e   Carvalho, Edgar M ^d   Almeida, Roque P ^e   Silva, João S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^e FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIMONY; ANTIPROTOZOAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE SEVERITY; FEMALE; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; INFLAMMATORY INFILTRATE; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE ISOLATION; PARASITE VIRULENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BRAZIL; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; RODENT DISEASE; SKIN; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; BRAZIL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; HUMANS; INTERLEUKIN-4; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; RODENT DISEASES; SKIN; TH1 CELLS; TH2 CELLS;

EID: 79953790901     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000965     Document Type: Article

References (64)

1. Brandao-Filho SP, Campbell-Lendrum D, Brito ME, Shaw JJ, Davies CR, (1999) Epidemiological surveys confirm an increasing burden of cutaneous leishmaniasis in north-east Brazil. Trans R Soc Trop Med Hyg 93: 488-494.
2. Follador I, Araújo C, Bacellar O, Araújo CB, Carvalho LP, et al. (2002) Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 34: 54-58.
3. Bittencourt A, Barral A, (1991) Evaluation of the histopathological classifications of american cutaneous and mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 86: 51-56.
4. Mendonca MG, de Brito ME, Rodrigues EH, Bandeira V, Jardim ML, et al. (2004) Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 189: 1018-1023.
5. McSorley S, Proudfoot L, O'Donnell CA, Liew FY, (1996) Immunology of murine leishmaniasis. Clin Dermatol 14: 451-464.
6. Bogdan C, Gessner A, Solbach W, Rollinghoff, M, (1996) Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 8: 517-525.
7. Biron C A, Gazzinelli RT, (1995) Effects of IL-12 in immune responses to microbial infections: a key mediator in regulating disease outcome. Curr Opin Immunol 7: 485-496.
8. Bogdan C, Rollighoff M, Diefenbach A, (2000) The role of nitric oxide in innate immunity. Immunol Rev 173: 17-26.
9. Liew FY, Parkinson C, Millott S, Severn A, Carrier M, (1990) Tumour necrosis factor (TNF alpha) in leishmaniasis II TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69: 570-573.
10. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
11. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, et al. (1999) Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 162: 7302-7308.
12. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udei MC, et al. (2001) The role of Interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
13. Padigel UM, Alexander J, Farrel JP, (2003) The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 171: 3705-3710.
14. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, (2002) CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
15. Belkaid Y, (2007) Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7: 875-887.
16. Rocha FJS, Schleicher U, Mattner J, Alber G, Bogdan C, (2007) Cytokines, signaling pathways and effector molecules in the control of Leishmania (Viannia) braziliensis. Infect Immun 75: 3823-3832.
17. Childs GE, Lighther LK, McKinney LA, Groves M, Price E, et al. (1984) Inbred mice as model hosts for cutaneous leishmaniasis. I. Resistance and susceptibility to infection with Leishmania braziliensis, L. mexicana and L. aethiopica. Ann Trop Med Parasitol 78: 25-34.
18. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P, (1994) Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 56: 315-325.
19. Faria DR, Gollob KJ, Barbosa-Junior J, Schriefer A, Machado PRL, et al. (2005) Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73: 7853-7859.
20. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceição-Silva F, et al. (1993) Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91: 1390-1395.
21. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM, (1998) Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31: 143-48.
22. Sassi A, Louzir H, Ben Salah A, Mokni M, Ben Osman A, et al. (1999) Leishmanin skin test lymphoproliferative response and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol 116: 127-132.
23. Carvalho EM, Correia-Filho D, Bacellar O, Almeida RP, Lessa H, et al. (1995) Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 53: 273-277.
24. Oliveira CI, Teixeira MJ, Teixeira CR, de Jesus JR, Rosato AB, et al. (2004) Leishmania braziliensis isolates differing at the genome level display distinctive features in BALB/c mice. Microbes Infect 6: 977-984.
25. Teixeira MJ, Fernández JD, Teixeira CR, Andrade BB, Pompeu ML, et al. (2005) Distinct Leishmania braziliensis isolates induce different paces of chemokine expression patterns. Infect Immun 73: 1191-1195.
26. Giudice A, Camada I, Leopoldo PT, Pereira JM, Riley LW, et al. (2007) Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in tegumentary leishmaniasis. BMC Infect Dis 22: 7.
27. Späth GF, Beverley SM, (2001) Lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol 99: 97-103.
28. Gamboa D, Torres K, De Doncker S, Zimic M, Arevalo J, et al. (2008) Evaluation of an in vitro and in vivo model for experimental infection with Leishmania (Viannia) braziliensis and L. (V.) peruviana. Parasitology 135: 319-326.
29. Souza AS, Giudice A, Pereira JMB, Guimarães LH, de Jesus AR, et al. (2010) Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production. BMC Infect Dis, 10: 209.
30. Pereira JC, Carregaro V, Costa DL, da Silva JS, Cunha FQ, et al. (2010) Antileishmanial activity of ruthenium(II)tetraammine nitrosyl complexes. Eur J Med Chem 45: 4180-4187.
31. de Moura TR, Novais FO, Oliveira F, Clarencio J, Noronha A, et al. (2005) Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect Immun 73: 5827-5834.
32. Moura TR, Oliveira F, Novais FO, Miranda JC, Clarêncio J, et al. (2007) Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis 28: e84.
33. Vargas-Inchaustegui D, Tai W, Xin L, Hogg AE, Corry DB, et al. (2009) Distinct roles for MyD88 and Toll-Like Receptor 2 during Leishmania braziliensis infection in mice. Infect Immun 77: 2948-2956.
34. Novais FO, Santiago RC, Báfica A, Khouri R, Afonso L, et al. (2009) Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J. Immunol 183: 8088-8098.
35. de Moura TR, Oliveira F, Rodrigues GC, Carneiro MW, Fukutani KF, et al. (2010) Immunity to Lutzomyia intermedia saliva modulates the inflammatory environment induced by Leishmania braziliensis. PLoS Negl Trop Dis 4: e712.
36. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.
37. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
38. Van Zandbergen G, Klinger M, Mueller A, Dannemberg S, Gebert A, et al. (2004) Cutting Edge: Neutrophil granulocytes serves as a vector for Leishmania entry into macrophages. J Immunol 173: 6521-25.
39. Peters NC, Egen JC, Secundino N, Debrabant A, Kimblin N, et al. (2008) In vivo imaging reveals essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321: 970-974.
40. Anderson CF, Oukka M, Kuchroo VJ, Sacks D, (2007) CD4+CD25-FoxP3- Th1 cells are the source of IL-10 mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
41. Nagase H, Jones KM, Anderson CF, Noben-Trauth N, (2007) Despite increased CD4+FoxP3+ cells within the infection site, BALB/c IL-4 deficient mice reveal CD4+FoxP3- T cells as a source of IL-10 in Leishmania major susceptibility. J Immunol 179: 2435-2444.
42. Campanelli AP, Roselino AM, Cavassani KA, Pereira MSF, Mortara RA, et al. (2006) CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory t cells. J Infect Dis 19: 1313-1322.
43. Mendez S, Reckling SK, Piccirillo CA, Sacks D, Belkaid Y, (2004) Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med 200: 201-210.
44. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y, (2006) Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777-788.
45. Yurchenko, E, Tritt M, Hay V, Shevach EM, Belkaid Y, et al. (2006) CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 203: 2451-2460.
46. Dekrey, GK, Lima HC, Titus RG, (1998) Analysis of the immune responses of mice to infection with Leishmania braziliensis. Infect Immun 66: 827-829.
47. Samuelson J, Lerner E, Tesh R, Titus R, (1991) A mouse model of Leishmania braziliensis infection produced by coinjection with sand fly saliva. J Exp Med 173: 49-54.
48. Ritter U, Lechner A, Scharl K, Kiafard Z, Zwirner J, et al. (2008) TNF-α controls the infiltration of dendritic cells into the site of Leishmania major infection. Med Microbiol Immunol 197: 29-37.
49. de Souza-Neto SM, Carneiro CM, Vieira LQ, Afonso LC, (2004) Leishmania braziliensis partial control of experimental infection by interleukin-12 p40 deficient mice. Mem Inst Oswaldo Cruz 99: 289-294.
50. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, et al. (2000) IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 164: 1458-1462.
51. Anderson P, (2000) Post-transcriptional regulation of tumour necrosis factor α production. Ann Rheum Dis 59: i3-i5.
52. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, et al. (2002) Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol 3: 673-680.
53. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, et al. (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202: 541-549.
54. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, et al. (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202: 1213-1223.
55. Kopf M, Brombacher F, Köhler G, Kienzle G, Widmann KH, et al. (1996) IL-4-deficient BALB/c mice resist infection with Leishmania major. J Exp Med 184: 1127-1136.
56. Castellano LR, Correia-Filho D, Argiro L, Dessein H, Prata A, et al. (2009) Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon- production. Hum Immunol 70: 383-390.
57. Munder M, (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158: 638-651.
58. Sonoki T, Nagasaki A, Gotoh T, Takiguchi M, Takeya M, et al. (1997) Coinduction of nitric-oxide synthase and arginase i in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J Biol Chem 272: 3689-3693.
59. Salimuddin, Nagasaki A, Gotoh T, Isobe H, Mori M, (1999) Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am J Physiol 277: E110-7.
60. Von Stebut E, (2007) Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17: 115-122.
61. Ritter U, Osterloh A, (2007) A new view on cutaneous dendritic cell subsets in experimental leishmaniasis. Med Microbiol Immunol 196: 51-59.
62. López-Bravo M, Ardavín C, (2008) In vivo induction of immune responses to pathogens by conventional dendritic cells. Immunity 29: 343-351.
63. Auffray C, Sieweke MH, Geissmann F, (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27: 669-692.
64. Biswas SK, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol 11: 889-896.